Clinical Trial Update: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab, alone or with other investigational agents, in participants with high-risk non-muscle invasive bladder cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED